title: Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
abstract: BACKGROUND
  Capecitabine, an oral alternative to 5-fluorouracil (5-FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns. In this study, the authors measured the cost of chemotherapy-related complications during treatment with capecitabine- and 5-FU-based regimens.
  
  
  METHODS
  Patients with CRC who received at least 1 administration of capecitabine or 5-FU during 2004 and 2005 were identified from the Thomson MarketScan research databases. Monthly frequency and cost for 23 complications were recorded. Logistic regression was used to predict complication probability. General linear models were used to predict monthly complication cost and total monthly expenditure.
  
  
  RESULTS
  In total, 4973 patients with CRC met the inclusion criteria for this analysis. Although the most frequently observed complications were the same between capecitabine and 5-FU (nausea and vomiting, infection, anemia, neutropenia, diarrhea), each was observed with greater frequency in 5-FU-based regimens. The mean predicted monthly complication cost was significantly higher (by 136%) with 5-FU monotherapy than with capecitabine monotherapy (difference, $601; 95% confidence interval [95% CI], $469-$737). In addition, the mean predicted monthly complication cost for 5-FU+oxaliplatin was higher than the cost with capecitabine plus oxaliplatin (difference, $1165; 95% CI, $892-$1595). When acquisition, administration, and complication costs were taken into consideration, there were no significant differences in the total cost between capecitabine regimens and 5-FU regimens.
  
  
  CONCLUSIONS
  Capecitabine compared well with 5-FU-based therapy in patients with CRC and was associated with lower complication rates and associated costs.
authors.affiliation: Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA. chueyale@yahoo.com
authors.forename: Edward
authors.initials: E
authors.lastname: Chu
authors.forename: Kathy L
authors.initials: KL
authors.lastname: Schulman
authors.forename: Susan
authors.initials: S
authors.lastname: Zelt
authors.forename: Xue
authors.initials: X
authors.lastname: Song
mesh_terms: D000368:Aged; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000191:economics*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics; D005252:Fees, Pharmaceutical; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000191:economics*; D005102:Health Expenditures; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil